Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | FLT4 | P35916 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.34 |
| ▸ | TEK | Q02763 | 1/20 | 0.34 |
| ▸ | TNF | P01375 | 2/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESRRA | P11474 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17981258 | 0.88 | NPC1 (0.38) | NPC1DGAT1LMNAMCL1EGFR | |
| SCHEMBL21649152 | 0.82 | TNF (0.33) | LMNAMCL1TNFMAPK8ESR1 | |
| SCHEMBL20401456 | 0.80 | PSMB1 (0.38) | NPC1DGAT1LMNAMCL1EGFR | |
| SCHEMBL27037221 | 0.80 | DGAT1 (0.38) | NPC1DGAT1EGFRIGF1RSRC | |
| SCHEMBL30698518 | 0.80 | DGAT1 (0.38) | NPC1DGAT1EGFRIGF1RSRC | |
| SCHEMBL38657054 | 0.79 | MCL1 (0.54) | DGAT1LMNAMCL1TP53POLB | |
| SCHEMBL17981263 | 0.79 | KDM4E (0.41) | NPC1DGAT1LMNAEGFRHSD17B10 | |
| SCHEMBL15155202 | 0.76 | PSMB5 (0.42) | NPC1DGAT1EGFRIGF1RSRC | |
| SCHEMBL26615066 | 0.76 | PSMB5 (0.52) | NPC1DGAT1EGFRIGF1RSRC | |
| SCHEMBL25697650 | 0.75 | DGAT1 (0.41) | NPC1DGAT1EGFRIGF1RSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200031811-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | BASILEA PHARM INT AG (CH) | 2020-01-30 | — | — | US | disclosed |
| US-20180002321-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | Basilea Pharmaceutica International AG (CH) | 2018-01-04 | — | — | US | disclosed |
| US-20180002321-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | Basilea Pharmaceutica International AG (CH) | 2018-01-04 | — | — | US | disclosed |
| EP-3256217-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | Basilea Pharmaceutica International AG (CH) | 2017-12-20 | — | — | EP | disclosed |
| WO-2016128465-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016128465-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002321-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | CBR3, SCO2, CBR1 | NPC1 1016/4885DGAT1 2429/4885LMNA 502/4885 |
| US-20200031811-A1 | SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE | CBR3, SCO2, CBR1 | NPC1 1018/4885DGAT1 2417/4885LMNA 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.